A bitter plant that quiets inflammatory signalling. The strongest case is the oldest: taken within a day or two of a cold or sore throat, it shortens and softens symptoms. Beyond that the picture thins. Stomach upset and skin reactions are common though mild, taste disturbance drives people to stop, and retail products are routinely below label. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT (alanine aminotransferase) | 10–26 U/L (men), 8–22 U/L (women) | Most sensitive marker of enzyme drift |
| AST (aspartate aminotransferase) | 10–26 U/L | Pairs with ALT: liver vs muscle origin |
| Total bilirubin | 0.3–1.0 mg/dL | Detects bile-flow impairment ALT can miss |
| hs-CRP | Below 1.0 mg/L | Target the anti-inflammatory case rests on |
| Fasting triglycerides | Below 80 mg/dL | Only metabolic endpoint with a positive trial |
| Complete blood count with differential | Eosinophils below 3% of white cells | Early objective signal of allergic response |
| eGFR | Above 90 mL/min/1.73 m² | Addresses the rodent kidney-toxicity signal |
| Fasting glucose | 75–86 mg/dL | Detects additive glucose lowering |
| Seated blood pressure | Below 120/80 mmHg | Catches additive hypotension |
Cadence: Baseline before the first dose. A 5–7 day respiratory course warrants no laboratory follow-up. Continuous use warrants a liver panel at 8–12 weeks, then every 6 months; lipids and inflammatory markers at 8–12 weeks, then annually.